Current workup for the pre-operative distinction between frequent adrenocortical adenomas (ACAs) and rare but aggressive adrenocortical carcinomas (ACCs) combines imaging and biochemical testing. We here investigated the potential of plasma steroid hormone profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) for the diagnosis of malignancy in adrenocortical tumors.
Retrospective cohort study of prospectively collected EDTA-plasma samples in a single tertiary reference center.
Steroid hormone profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) in random plasma samples and logistic regression modeling.
Fifteen steroid hormones were quantified in 66 ACAs (29 males; M) and 42 ACC (15 M) plasma samples. Significantly higher abundances in ACC vs ACA were observed for 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, 11-deoxycortisol, DHEA, DHEAS and estradiol (all P < 0.05). Maximal areas under the curve (AUC) for discrimination between ACA and ACC for single analytes were only 0.76 (estradiol) and 0.77 (progesterone), respectively. Logistic regression modeling enabled the discovery of diagnostic signatures composed of six specific steroids for male and female patients with AUC of 0.95 and 0.94, respectively. Positive predictive values in males and females were 92 and 96%, negative predictive values 90 and 86%, respectively.
This study in a large adrenal tumor patient cohort demonstrates the value of plasma steroid hormone profiling for diagnosis of ACC. Application of LC-MS/MS analysis and of our model may facilitate diagnosis of malignancy in non-expert centers. We propose to continuously evaluate and improve diagnostic accuracy of LC-MS/MS profiling by applying machine-learning algorithms to prospectively obtained steroid hormone profiles.
FassnachtMArltWBancosIDralleHNewell-PriceJSahdevATabarinATerzoloMTsagarakisSDekkersOM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology2016175G1–G34. (https://doi.org/10.1530/EJE-16-0467)
BolandGWLeeMJGazelleGSHalpernEFMcNicholasMMMuellerPR.Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. American Journal of Roentgenology1998171201–204. (https://doi.org/10.2214/ajr.171.1.9648789)
KorobkinMGiordanoTJBrodeurFJFrancisIRSiegelmanESQuintLEDunnickNRHeikenJPWangHH.Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology1996200743–747. (https://doi.org/10.1148/radiology.200.3.8756925)
KebebewEReiffEDuhQYClarkOHMcMillanA.Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?World Journal of Surgery200630872–878. (https://doi.org/10.1007/s00268-005-0329-x)
KerkhofsTMVerhoevenRHVan der ZwanJMDielemanJKerstensMNLinksTPVan de Poll-FranseLVHaakHR.Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. European Journal of Cancer2013492579–2586. (https://doi.org/10.1016/j.ejca.2013.02.034)
TerzoloMAngeliAFassnachtMDaffaraFTauchmanovaLContonPARossettoRBuciLSperonePGrossrubatscherEet al. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine20073562372–2380. (https://doi.org/10.1056/NEJMoa063360)
BerrutiAGrisantiSPulzerAClapsMDaffaraFLoliPMannelliMBoscaroMArvatETiberioGet al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism20171021358–1365. (https://doi.org/10.1210/jc.2016-2894)
MegerleFHerrmannWSchloetelburgWRonchiCLPulzerAQuinklerMBeuschleinFHahnerSKroissMFassnachtMet al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism20181031686–1695. (https://doi.org/10.1210/jc.2017-02591)
GowerDBSternMI.Steroid excretion and biosynthesis, with special reference to androst-16-enes, in a woman with a virilising adrenocortical carcinoma. Acta Endocrinologica196960265–275. (https://doi.org/10.1530/acta.0.0600265)
GowerDBDalyJRSnodgrassGJSternMI. Steroid excretion and biosynthesis with special reference to C19-delta16-steroids in an infant with a virilizing adrenocortical carcinoma. Acta Endocrinologica197063562–576. (https://doi.org/10.1530/acta.0.0630562)
ArltWBiehlMTaylorAEHahnerSLibeRHughesBASchneiderPSmithDJStiekemaHKroneNet al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. Journal of Clinical Endocrinology and Metabolism2011963775–3784. (https://doi.org/10.1210/jc.2011-1565)
KerkhofsTMAKerstensMNKemaIPWillemsTPHaakHR.Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors. Hormones and Cancer20156168–175. (https://doi.org/10.1007/s12672-015-0224-3)
VogeserMParhoferKG.Liquid chromatography tandem-mass spectrometry (LC-MS/MS) – technique and applications in endocrinology. Experimental and Clinical Endocrinology and Diabetes2007115559–570. (https://doi.org/10.1055/s-2007-981458)
MonaghanPJKeevilBGTrainerPJ.The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Reviews in Endocrine and Metabolic Disorders201314143–157. (https://doi.org/10.1007/s11154-013-9240-1)
TaylorDRGhataoreLCouchmanLVincentRPWhitelawBLewisDDiaz-CanoSGalataGSchulteKMAylwinSet al. A 13-steroid serum panel based on LC-MS/MS: use in detection of adrenocortical carcinoma. Clinical Chemistry2017631836–1846. (https://doi.org/10.1373/clinchem.2017.277624)
Di DalmaziGFanelliFMezzulloMCasadioERinaldiEGarelliSGiampalmaEMosconiCGolfieriRVicennatiVet al. Steroid profiling by LC-MS/MS in nonsecreting and subclinical cortisol-secreting adrenocortical adenomas. Journal of Clinical Endocrinology and Metabolism20151003529–3538. (https://doi.org/10.1210/JC.2015-1992)
VanDerWalJFalconiLJanuchowskiSShooLStorlieC.Species Distribution Modelling Tools: Tools for Processing Data Associated With Species Distribution Modelling Exercises. https://CRAN.R-project.org/package=SDMTools2014.
ShackletonCH.Congenital adrenal hyperplasia caused by defect in steroid 21-hydroxylase. Establishment of definitive urinary steroid excretion pattern during first weeks of life. Clinica Chimica Acta197667287–298. (https://doi.org/10.1016/0009-8981(76)90337-5)
CaulfieldMPLynnTGottschalkMEJonesKLTaylorNFMalunowiczEMShackletonCHReitzREFisherDA.The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens. Journal of Clinical Endocrinology and Metabolism2002873682–3690. (https://doi.org/10.1210/jcem.87.8.8712)
KroneNReischNIdkowiakJDhirVIvisonHEHughesBARoseITO’NeilDMVijzelaarRSmithMJet al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Journal of Clinical Endocrinology and Metabolism201297E257–E267. (https://doi.org/10.1210/jc.2011-0640)
KamrathCHartmannMFBoettcherCZimmerKPWudySA.Diagnosis of 21-hydroxylase deficiency by urinary metabolite ratios using gas chromatography-mass spectrometry analysis: reference values for neonates and infants. Journal of Steroid Biochemistry and Molecular Biology201615610–16. (https://doi.org/10.1016/j.jsbmb.2015.10.013)
MinowadaSKinoshitaKHaraMIsurugiKUchikawaTNiijimaT.Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. Endocrinologia Japonica19853229–37. (https://doi.org/10.1507/endocrj1954.32.29)
GrondalSErikssonBHagenasLWernerSCurstedtT.Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinologica1990122656–663. (https://doi.org/10.1530/acta.0.1220656)
KerkhofsTMKerstensMNKemaIPWillemsTPHaakHR.Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors. Hormones and Cancer20156168–175. (https://doi.org/10.1007/s12672-015-0224-3)